What the agency is buying
by RFPFinder from the notice; the solicitation governsThe U.S. Department of Defense is seeking parties interested in participating in the Generally Unconstrained Intelligence Drug Engineering (GUIDE) program.
Scope
- The GUIDE Program will be carried out under the terms of a Participant Basic Agreement (PBA).
How to get the bid documents
- Open the notice on SAM.gov
- Read the notice; the source lists no attachments
- Submit by email before 12:00 PM ET on Oct 18, 2028
The source notice lists no attachments.
Open the original listing on SAM.govDetails
- Place of performance
- Frederick, Maryland
- Buyer type
- Federal
- Notice type
- Special Notice
- Solicitation no.
- W911SR-25-S-GUIDE
- Period of performance
- Per award from notice
- BAA open until
- Oct 18, 2028 from notice
- Contract type
- BAA (multiple awards) from notice
- Evaluation
- White-paper review, then invited proposals (FAR 35.016) from notice
- Local presence
- Not required
- Amendments
- 7, last Oct 8
- Contact
- Joseph McCaffery
- Office
- DEPT OF THE ARMY · W6QK ACC-APG
Not stated in the notice: estimated value. Check the bid documents.
Contact details from the source notice. Contact the buyer only about this solicitation.
Key dates
- Amendment 1
- Fri, Oct 18, 2024
- Amendment 2
- Fri, Jun 13, 2025
- Amendment 3
- Mon, Dec 1, 2025
- Amendment 4
- Mon, Dec 1, 2025
- Amendment 5
- Wed, Sep 23, 2026
- Amendment 6
- Wed, Oct 7, 2026 · The original solicitation notice has been updated with additional information about the GUIDE Program and the Participant Basic Agreement (PBA) process.
- Amendment 7
- Thu, Oct 8, 2026 · The original solicitation notice has been updated with additional information about the GUIDE Program and the Participant Basic Agreement (PBA) process.
Change log
verified Thu, Oct 8 · 12:38 AM ET- Posted · Special NoticeFri, Oct 18, 2024 · 5:28 AM ET
- Amendment · New version of the notice posted at the sourceFri, Oct 18, 2024 · 5:28 AM ET
- Amendment · New version of the notice posted at the sourceFri, Jun 13, 2025 · 4:46 AM ET
- Amendment · New version of the notice posted at the sourceMon, Dec 1, 2025 · 8:19 AM ET
- Amendment · New version of the notice posted at the sourceMon, Dec 1, 2025 · 8:40 AM ET
- Amendment · New version of the notice posted at the sourceWed, Sep 23, 2026 · 11:27 AM ET
- Amendment · The original solicitation notice has been updated with additional information about the GUIDE Program and the Participant Basic Agreement (PBA) process.Wed, Oct 7, 2026 · 12:35 AM ET
- Updated · description text changedThu, Oct 8, 2026 · 12:31 AM ET
- Updated · description text changedThu, Oct 8, 2026 · 12:33 AM ET
- Updated · description text changedThu, Oct 8, 2026 · 12:33 AM ET
- Updated · description text changedThu, Oct 8, 2026 · 12:38 AM ET
- Updated · description text changedThu, Oct 8, 2026 · 12:38 AM ET
- Amendment · The original solicitation notice has been updated with additional information about the GUIDE Program and the Participant Basic Agreement (PBA) process.Thu, Oct 8, 2026 · 12:38 AM ET
Report a problem
Notice as published
Generally Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and industry partners
W911SR-25-S-GUIDE Notice Type: Special Announcement Synopsis: This is a solicitation for parties interested in participating in projects sought by the The Joint Project Lead Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies (JPL-CBRND-EB) (JPL EB). JPL EB has the mission to accelerate the delivery of medical countermeasures to the warfighter through the development and implementation of platform systems. Generally Unconstrained Intelligence Drug Engineering (GUIDE) is an integrated computational and experimental platform designed to accelerate medical countermeasure development.
GUIDE harnesses the power of advanced simulation and machine learning to enable preparedness and facilitate rapid response to protect the warfighter from a diverse and dynamic threat space. GUIDE impacts the discovery and design of biological products (e.g., monoclonal antibodies and vaccines) as well as small molecule drugs by simultaneously optimizing critical quality attributes of safety, efficacy, manufacturability and pharmacokinetics/pharmacodynamics while concurrently accounting for critical design attributes affecting developability and biophysical properties. GUIDE is a collaboration between U.S. interagency, academic and industry partners and is closely linked to the Accelerated Antibodies, Rapid Access to Products in Development (RAPID), Vaccine Acceleration by Modular Progression (VAMP), and Rapid Acquisition and Investigation of Drugs for Repurposing (RAIDR) programs.
Additional information may be found at: https://armyeitaas.sharepoint-mil.us/sites/usaasc-jpeocbrnd The GUIDE Program will be carried out under the terms of a Participant Basic Agreement (PBA). The PBA is available for qualified entities interested in participating. Entities wishing to participate shall submit an email requesting participation to the Primary Point of Contact identified below demonstrating technical relevancy and ecency in development of Medical Countermeasures.
Material that is only advertisement or marketing material in nature is not desired. Entities requesting participation will be reviewed by the program office to determine their technical relevance to the program, and subsequently invited to participate as a qualified entity. Projects awarded resulting from participation in the GUIDE Program may be awarded under authority 10 U.S.C.
4022 and 10 U.S.C. 4023. Agreements awarded pursuant to 10 U.S.C.
4022 and 10 U.S.C. 4023 will NOT be made or issued under the provisions of the Competition in Contracting Act of 1984 (P.L. 98-369), FAR Part 6 or any other FAR based regulation.
The U.S. Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Edgewood Contracting Division is supporting JPL EB in the execution of the GUIDE Program.
Primary Point of Contacts: Richard Totten Email Address: [email on the source notice] Joseph McCaffery Email Address: [email on the source notice] Alexander Mallette Email Address: [email on the source notice] Please send technical and administrative questions and inquiries to the Primary Point of Contacts to facilitate communication on all matters relating to this Announcement. The Government is prohibited from soliciting and awarding actions to contractors that have engaged or are suspected to have engaged in criminal, fraudulent, or seriously improper conduct. Prospective vendors shall complete electronic annual representations and certifications at SAM.
There is a requirement that prospective awardees MUST be registered in the System for Award Management (SAM) database prior to submitting an invoice and through final payment of any agreement resulting from any award. Vendors that are not registered should consider applying for registration immediately. To remain registered in the SAM database after the initial registration, the Vendors is required to review and update on an annual basis from the date of initial registration (or subsequent updates) its information in the SAM database to ensure it is current, accurate and complete.
This notification is for planning purposes only. It is not to be construed as a commitment by the Government nor will the Government pay for the information solicited.
Similar Dept of the Army awards · PSC AC13
USAspending.gov, last 36 months25 awards matched · tier 2: Dept of the Army + PSC AC13; nothing from this office. Most recent:
Pro shows every award with the recipient, amount, period and a link to the award record, plus a CSV export. $39/mo.
Sign in or upgradeAwards updated Tue, Oct 6, 2026 · 5:34 AM ET.
This contracting office
62 other open notices from this office · buys mostly Other, Supplies & Equipment, IT & Software
Similar open RFPs
same PSC AC13Listing collected from SAM.gov. Always confirm requirements in the original solicitation before you bid.